Department of Medicine, Joe R. and Teresa Lozano Long School of Medicine, University of Texas Health San Antonio (UT Health San Antonio), San Antonio, TX, USA.
Center for Research to Advance Community Health (ReACH), UT Health San Antonio, San Antonio, TX, USA.
J Gen Intern Med. 2018 Sep;33(9):1498-1503. doi: 10.1007/s11606-018-4526-3. Epub 2018 Jun 8.
The Chronic Care Model (CCM) has been endorsed by experts to reduce disparities in chronic disease outcomes but benefits may be slow to appear in low-income populations.
To evaluate the effect of CCM implementation on systolic blood pressure (SBP) control in minority patients with diabetes mellitus (DM).
Retrospective study from 2012 to 2016 in two primary care clinics with primarily uninsured, Hispanic patients.
Four 2-year cohorts of patients aged 18-75 with DM and SBP ≥ 140 mmHg on HTN drugs in year 1 and SBP measured 1 year later in year 2.
Implementation of CCM for DM in January 2014 involved: electronic medical record revision, a DM registry, hypertension (HTN) treatment protocol, team education, performance feedback, and case management.
SBP < 140 mmHg in year 2.
Of 2354 patients, the mean age was 56.2 (SD 9.5), baseline SBP 153.8 (SD 14.9) mmHg, and 79.8% Hispanic. Last SBP < 140 mmHg was 58.4% for cohort 1 (2012-2013) and 68.5% for cohort 4 (2015-2016). Adjusted odds ratios (AORs) for SBP control versus cohort 1 were 1.35 (95% CI 1.07, 1.69) for cohort 3 (2014-2015) and 2.13 (95% CI 1.60, 2.80) for cohort 4. AORs for SBP control were reduced by 15% per HTN drug at baseline (P = 0.001), 9% per HTN drug added at last SBP (P = 0.024), and 22% for multi-dose HTN drugs (P = 0.004). Among patients with persistent elevated SBP and represented in multiple cohorts, AORs for control were still over 2-fold higher for cohort 4 versus cohort 1.
After adopting the CCM for primarily Hispanic patients with DM, SBP control increased significantly despite treatment with fewer HTN drugs. Yet improvement took 3-4 years, suggesting that financial rewards for using the CCM to achieve improved clinical outcomes for low-income, minority patients may be delayed.
慢性照护模式(CCM)已得到专家认可,可以降低慢性病结局的差异,但在低收入人群中,其益处可能需要较长时间才能显现。
评估 CCM 实施对糖尿病患者收缩压(SBP)控制的影响,这些患者以少数民族为主。
2012 年至 2016 年在两家初级保健诊所进行的回顾性研究,主要纳入未参保的西班牙裔患者。
纳入 4 组年龄在 18-75 岁之间的患者,他们在第 1 年使用降压药物治疗时收缩压(SBP)≥140mmHg,在第 2 年时测量了 1 年后的 SBP。
2014 年 1 月对糖尿病患者实施 CCM,包括:电子病历修订、糖尿病登记册、高血压(HTN)治疗方案、团队教育、绩效反馈和病例管理。
第 2 年 SBP<140mmHg。
2354 例患者中,平均年龄为 56.2(SD 9.5)岁,基线 SBP 为 153.8(SD 14.9)mmHg,其中 79.8%为西班牙裔。第 1 组(2012-2013 年)最后一次 SBP<140mmHg的比例为 58.4%,第 4 组(2015-2016 年)为 68.5%。与第 1 组相比,第 3 组(2014-2015 年)SBP 控制的调整后比值比(AOR)为 1.35(95%CI 1.07,1.69),第 4 组(2015-2016 年)为 2.13(95%CI 1.60,2.80)。基线时每增加一种降压药物,SBP 控制的 AOR 降低 15%(P=0.001),最后一次 SBP 时每增加一种降压药物,AOR 降低 9%(P=0.024),多剂量降压药物时降低 22%(P=0.004)。在多次 SBP 升高且在多个队列中出现的患者中,第 4 组的 AOR 仍高于第 1 组,比值仍超过 2 倍。
在为主要以西班牙裔为主的糖尿病患者采用 CCM 后,尽管降压药物的使用减少,但 SBP 控制显著增加。然而,改善需要 3-4 年,这表明对使用 CCM 来改善低收入、少数民族患者的临床结局的经济奖励可能会延迟。